The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
about
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorderFrom pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatmentConstruction of drug network based on side effects and its application for drug repositioningImproving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures.The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder.The effects of gender and catechol O-methyltransferase (COMT) Val108/158Met polymorphism on emotion regulation in velo-cardio-facial syndrome (22q11.2 deletion syndrome): An fMRI studyPharmacogenetics of antidepressant response.Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life.Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.Pharmacogenetics of antidepressantsCatechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.The promise and reality of pharmacogenetics in psychiatryPharmacogenomic strategy for individualizing antidepressant therapy.Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.Mirtazapine: a review of its clinical efficacy and tolerability.Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders.No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression.COMT Val(158) Met genotype is associated with reward learning: a replication study and meta-analysisPharmacogenetics of antidepressant response: an updatePersonalized medicine for depression: can we match patients with treatments?Genetics of depression: an overview of the current science.Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression.Role of COMT, 5-HT(1A) , and SERT genetic polymorphisms on antidepressant response to Transcranial Magnetic Stimulation.A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.Association of TMEM132D, COMT, and GABRA6 genotypes with cingulate, frontal cortex and hippocampal emotional processing in panic and major depressive disorder.The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.Imaging genetics: implications for research on variable antidepressant drug response.Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.The potential of pharmacogenomics to treat drug addiction.Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder
P2860
Q24652360-32C34C4F-E825-4412-B36B-CFCAFB33AFCFQ27015830-AFE0C73B-B9A3-43BA-B75E-B2FD8AA58577Q28539501-21DB7F27-19F4-45CE-BB1C-3E1606D842FFQ33404025-89115916-6F2A-42AD-B341-94139294B9A9Q33756672-9370458D-12BA-4B62-AAC7-4C68FC4098DDQ34005465-5BA8CC41-3D25-4F16-9728-66C7097D6A78Q34155796-6AEC4A1E-C674-4250-8574-0E1001F55877Q34424865-6E375D4C-06DE-4AF6-9413-424677A55DE1Q34473840-F36F0BDF-755D-474A-AF4A-E2184B61357CQ34661215-7BE51B85-84A8-4BBF-9E65-AA76AD2105F9Q34871885-E51B921F-3D38-475C-9BC4-EDBCA39BA7EBQ35026088-34B57E2A-9E72-482A-B2CE-A4D71EEA982AQ35040545-12A6C0E1-0440-423F-815A-92FFE759AA6EQ35226451-969FBAF9-121E-49DF-A95E-E5A85F57E1D3Q35237038-EDC796F5-3F5B-4B7F-88CE-3D772472E0D2Q35237042-8C7BD153-0CF2-4C99-A95A-3C8AB1DBECD4Q36150725-4DFE4EF2-D98D-46CD-9561-99A1C20DFA84Q36441426-94BFD826-378F-4A52-BF41-FF3ED249B058Q36941592-946B2F1B-0754-41A5-83B9-115014142CBDQ36963549-30FE6945-2CB4-4C92-8911-B73BD3D7F134Q37464458-88F849C4-D1FB-4CFB-9700-C96CA23005E3Q37789098-18049BFF-A37F-47AA-95C4-25A1E57F71F7Q37847575-EA10144A-98B8-4A45-8D59-13E25ACED2E4Q37989490-719CC729-8429-49DE-B9BF-D7A827CB90E5Q38121519-58423623-912C-4DAD-A130-E1FEA845AEAAQ38657429-B1405FDC-11F7-4CC6-A7CB-DD38C0F05A54Q38731079-CD41E507-B530-4AC4-B4FC-1BB69A12E8F0Q38983579-6F0B0F48-E0CA-47A7-AF1C-1C7A92ECB434Q42392736-BD5A0766-D722-4B64-9836-188F556D2478Q42595600-57740C92-F549-419A-AC18-E6DC8361B8A1Q46726992-4E55A28B-1FFE-4F41-BDED-F50059CECD1AQ47666907-7C8D8151-7804-4FE2-81D4-53A994F576AEQ47699968-CBFA8F12-3042-4C9F-B2D7-80054F205E9AQ47852468-9914DD75-32B3-4EF9-AF3D-9A9A80317F3CQ48148747-846137FC-24B0-4262-8B8D-4365701F2F60Q48348353-05425718-1C33-4C90-A183-B8F9EA3BFB4DQ48588111-D7757F69-AA60-4044-97A6-85252241C73FQ52295623-06E60D8A-B315-44AB-9E1A-395CF1B759E2Q58887973-A97FE363-B622-4FB1-8B4F-A1A57C2D3C85
P2860
The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The catechol-O-methyltransfera ...... aroxetine in major depression.
@en
The catechol-O-methyltransfera ...... aroxetine in major depression.
@nl
type
label
The catechol-O-methyltransfera ...... aroxetine in major depression.
@en
The catechol-O-methyltransfera ...... aroxetine in major depression.
@nl
prefLabel
The catechol-O-methyltransfera ...... aroxetine in major depression.
@en
The catechol-O-methyltransfera ...... aroxetine in major depression.
@nl
P2093
P2860
P356
P1476
The catechol-O-methyltransfera ...... aroxetine in major depression.
@en
P2093
Stassen HH
P2860
P2888
P356
10.1038/SJ.TPJ.6500289
P577
2005-01-01T00:00:00Z
P5875
P6179
1003040894